A phase IIa randomized, double-blind, parallel-groups, placebo controlled clinical trial to study the efficacy and safety of MK0724 [arundic acid] intravenous infusion on the amelioration of neurological damage and recovery middle cerebral artery ischemic stroke
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2014
At a glance
- Drugs Arundic acid (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Merck & Co
- 03 Nov 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 Feb 2009 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
- 16 Nov 2008 Status changed from recruiting to active, no longer recruiting, as reported in ClinicalTrials.gov.